A problem to be solved by the present invention is to provide a method of assisting diagnosis of the health condition of a subject by correcting variation in an amount of a collected disease marker, which is caused by variation in the skin barrier function of the subject, and acquiring information reflecting the health condition of the subject accurately, and to solve the problem, the present invention provides a method of assisting diagnosis of a disease in a subject using a disease marker and a reference marker, the method including: applying, to a skin surface of the subject, a sheet capable of generating an attractive force due to electrostatic interaction between the sheet and each of the disease and reference markers; detaching the sheet from the skin surface; measuring the amount of each of the disease and reference markers that are attached to the sheet; and acquiring information on the disease in the subject based on a value obtained by correcting the measured amount of the disease marker with the measured amount of the reference marker, wherein the reference marker is annexin A2.

Systems and methods are provided for improving skincare product formulations to address predicted skin trends. A biomarker analysis system is used to determine concentrations of various protein biomarkers of a user. A skin diagnosis computing device uses the protein biomarker concentrations to determine one or more skin trends, and determines one or more skincare product ingredients to address the skin trends. A skincare product is compounded that includes the one or more skincare product ingredients.

In some embodiments, protein biomarker concentration information for a subject is obtained, and is used to determine one or more skin trends likely to be experienced by the subject. Skincare product recommendations are generated based on the protein biomarker concentration information. Feedback on the recommended skincare products may be received, and may be used to improve future recommendations for skincare products for the subject or for other subjects.

A method, assay, peptide and antibody that forms an antibody-antigen conjugate with the peptide comprising the amino acid sequence: GPPPPPGKPQGPPPQGGNKPQGPPPPGKPQGPPAQGGSKSQSARAPPGKPQGPPQQEGNNPQGPPPPAGGNPQQPQAPP or an amino acid sequence that is at least 75% identical to said sequence, and the formation of an antigen-antibody conjugate is a positive indicator for Sjgren's Syndrome.

The present invention provides a method for determining a sensitivity to ultraviolet light non-invasively and immediately. A method for determining a UV sensitivity is provided involving: a step of irradiating the skin of a test subject with ultraviolet light to determine the UV sensitivity using the amount of biophotons to be detected within a specific period after the irradiation, wherein 50% or more of the specific period overlaps a period from 1 to 3 minutes after the irradiation.

Described herein are monoclonal antibodies, assay kits and immumoassay methods for quantifying elastin fragments having a C-terminus amino acid sequence LPGGYGLPYT (SEQ ID NO: 1) in a patient biofluid sample, and uses thereof for detecting or quantifying fibrotic diseases such as chronic obstructive lung disease (COPD).

The present invention is related to novel methods for identifying a population of subjects that are at risk for developing of atopic allergic diseases, and to the prevention of these allergic diseases.

This invention related to a method for diagnosing a skin displaying signs of aging, based on measuring the level of expression of the gene encoding the IDE. The present invention also relates to a method for the cosmetic treatment of skin. This invention also relates to a method for identifying a compound for reducing the signs of the aging of the skin as well as a kit.

Disclosed herein is a method of detecting the presence of skin UV damage based on molecular risk factors. In some instances, also described herein is a method of determining the progression of UV damage based on the molecular risk factors.

This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.